Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction
Autore:
Vitezic, D;
Indirizzi:
Univ Rijeka, Sch Med, Dept Pharmacol, Clin Pharmacol, HR-51000 Rijeka, Croatia Univ Rijeka Rijeka Croatia HR-51000 Pharmacol, HR-51000 Rijeka, Croatia Univ Hosp Ctr Rijeka, Dept Sci & Clin Pharmacol, HR-51000 Rijeka, Croatia Univ Hosp Ctr Rijeka Rijeka Croatia HR-51000 l, HR-51000 Rijeka, Croatia
Titolo Testata:
DRUG SAFETY
fascicolo: 4, volume: 24, anno: 2001,
pagine: 255 - 265
SICI:
0114-5916(2001)24:4<255:ARAOSI>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOSE YOHIMBINE HYDROCHLORIDE; ORAL SILDENAFIL; DOUBLE-BLIND; NITRIC-OXIDE; TRANSURETHRAL ALPROSTADIL; CARDIOVASCULAR-DISEASE; CORPUS CAVERNOSUM; CITRATE; EFFICACY; VIAGRA;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
72
Recensione:
Indirizzi per estratti:
Indirizzo: Vitezic, D Univ Rijeka, Sch Med, Dept Pharmacol, Clin Pharmacol, Brace Branchetta 20,HR-51000 Rijeka, Croatia Univ Rijeka Brace Branchetta 20 RijekaCroatia HR-51000 roatia
Citazione:
D. Vitezic, "A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction", DRUG SAFETY, 24(4), 2001, pp. 255-265

Abstract

Sildenafil is an oral treatment for erectile dysfunction (ED). It acts as an inhibitor of 3',5'-cyclic guanosine monophosphate-phosphodiesterase type5, An effective treatment for ED is required to produce an erectile response sufficient for satisfactory sexual performance. This has been documentedfor sildenafil in men with ED of differing aetiologies and baseline severity in various types of clinical trials. Sildenafil treatment is characterised by a good tolerability profile and low treatment discontinuation rate caused by treatment-related adverse effects. Most of the adverse effects associated with sildenafil are extensions of the pharmacological action of the drug. There is no significant difference in the adverse effect profile (headache, flushing, dyspepsia, nasal congestion and abnormal vision) of this agent as assessed by clinical data obtained either in the pre- and postlaunch periods. Because of its acceptable risk-benefit ratio, sildenafil can be prescribed to a very large group of patients with ED. The reports of serious cardiovascular events associated withthe use of sildenafil (including anecdotal reports of deaths) have been very thoroughly analysed. A number of studies have not shown any difference in the risk of serious cardiovascular events in sildenafil- and placebo-treated patients. However, when making a risk-benefit evaluation, certain subgroups of patients need to be considered separately. In particular, sildenafil is contraindicated in patients receiving nitrate therapy. In some other subgroups of patients, the risks and benefits of treatment need to be assessed on an individual basis and it is hoped that additional data will clarifyany possible risks associated with sildenafil administration such patients. It is helpful to compare the risk-benefit profile of sildenafil with the characteristics of other oral drugs far ED. According to the preliminary data, apomorphine and phentolamine are possible future options for the treatment of ED; however, there needs to be further clinical evaluation of these agents. Initial data have shown that sildenafil can be successfully combinedwith intracavernosal injection in patients nonresponders to either therapy. In conclusion, favourable characteristics make sildenafil suitable for thefirst-line therapy for a substantial proportion of patients with ED.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 12:40:15